Skip to main content

First Tracks Biotherapeutics, Inc 10-Q for FY2026 Q3

First Tracks Biotherapeutics, Inc. (TRAX)

10-Q 2026-11-03 For: 2026-09-30
View Original
Added on November 03, 2026

About this 10-Q

First Tracks Biotherapeutics, Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$31.36M
compared with a net loss of $41.86M a year earlier
Diluted EPS
-$0.88
compared with -$1.50 a year earlier